Alpha5beta1 Integrin Inhibitors for Asthma Treatment
Solution Overview
Problem
Current therapeutic options for asthma are limited, and there is a need for potent and selective α5β1 integrin inhibitors to modulate the α5β1 integrin for effective treatment.
Innovation Solution
Development of compounds with specific formulas that act as α5β1 inhibitors, which can be administered to treat asthma, cancer, inflammatory diseases, and autoimmune diseases by inhibiting α5β1 integrin activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic options are used for asthma, then treatment is available, but the treatments are not effective enough due to limited options
Solution Approach 1:
The patent applies parameter changes by developing small molecule inhibitors with specific chemical structures (Formula 1 and its variants) that target the α5β1 integrin. By modifying molecular parameters such as substituent groups (R1-R10), linkers (L1-L4), and core structures, the invention creates a series of compounds with optimized binding affinity and selectivity for α5β1 integrin, thereby improving treatment effectiveness while providing multiple therapeutic options for asthma and other diseases.
2Measurement precision
If α5β1 integrin inhibitors are developed, then selective targeted therapy is achieved, but the complexity of drug development increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core structure (various aromatic rings, heterocycles), substituent groups (R1-R10 with specific chemical properties), and linkers (L1-L4). This modular segmentation allows for systematic optimization of selectivity toward α5β1 integrin while managing structural complexity through organized variation of discrete components rather than random complexity.
3Reliability
If potent α5β1 integrin inhibitors are created, then therapeutic efficacy is improved, but the difficulty of achieving selectivity over other integrins increases
Solution Approach 1:
The patent applies local quality by designing specific local features in the inhibitor molecules that confer selectivity for α5β1 integrin. This includes particular substituent patterns (e.g., R3 as hydrogen, alkyl, or heteroalkyl; R4 as hydrogen or alkyl), specific linker types (L3 as bond, —O—, —S—, or —N(R7)—), and core structures that create unique binding interactions with α5β1 integrin's binding pocket, thereby achieving both potency and selectivity through localized molecular features.
Data Source
AI summary
Disclosed herein, inter alia, are inhibitors of integrin alpha 5 beta 1 and methods of using the same.